Economic evaluation of toripalimab combined with chemotherapy in the treatment of non-small cell lung cancer.
Frontiers in public health（2023）
摘要
From the viewpoint of the Chinese healthcare system, toripalimab combined with chemotherapy in the treatment of advanced NSCLC with negative driver genes was likely to be cost-effective compared with chemotherapy.
更多查看译文
关键词
chemotherapy,cost-effectiveness analysis,non-small cell lung cancer,partition survival model,toripalimab
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要